Anti-ANKRD42 monoclonal antibody

Pre-made anti-ANKRD42 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ANKRD42/ANKRD42 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2345-Ab-1/ GM-Tg-hg-IP2345-Ab-2Anti-Human ANKRD42 monoclonal antibodyHuman
GM-Tg-rg-IP2345-Ab-1/ GM-Tg-rg-IP2345-Ab-2Anti-Rat ANKRD42 monoclonal antibodyRat
GM-Tg-mg-IP2345-Ab-1/ GM-Tg-mg-IP2345-Ab-2Anti-Mouse ANKRD42 monoclonal antibodyMouse
GM-Tg-cynog-IP2345-Ab-1/ GM-Tg-cynog-IP2345-Ab-2Anti-Cynomolgus/ Rhesus macaque ANKRD42 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2345-Ab-1/ GM-Tg-felg-IP2345-Ab-2Anti-Feline ANKRD42 monoclonal antibodyFeline
GM-Tg-cang-IP2345-Ab-1/ GM-Tg-cang-IP2345-Ab-2Anti-Canine ANKRD42 monoclonal antibodyCanine
GM-Tg-bovg-IP2345-Ab-1/ GM-Tg-bovg-IP2345-Ab-2Anti-Bovine ANKRD42 monoclonal antibodyBovine
GM-Tg-equg-IP2345-Ab-1/ GM-Tg-equg-IP2345-Ab-2Anti-Equine ANKRD42 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2345-Ab-1/ GM-Tg-hg-IP2345-Ab-2; GM-Tg-rg-IP2345-Ab-1/ GM-Tg-rg-IP2345-Ab-2;
GM-Tg-mg-IP2345-Ab-1/ GM-Tg-mg-IP2345-Ab-2; GM-Tg-cynog-IP2345-Ab-1/ GM-Tg-cynog-IP2345-Ab-2;
GM-Tg-felg-IP2345-Ab-1/ GM-Tg-felg-IP2345-Ab-2; GM-Tg-cang-IP2345-Ab-1/ GM-Tg-cang-IP2345-Ab-2;
GM-Tg-bovg-IP2345-Ab-1/ GM-Tg-bovg-IP2345-Ab-2; GM-Tg-equg-IP2345-Ab-1/ GM-Tg-equg-IP2345-Ab-2
Products NameAnti-ANKRD42 monoclonal antibody
Formatmab
Target NameANKRD42
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-ANKRD42 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2345-Ag-1Recombinant multi-species ANR42/ ANKRD42/ PPP1R79 protein


    Target information

    Target IDGM-IP2345
    Target NameANKRD42
    Gene ID338699,73845,293117,701791,100688339,101099243,522004,100061659
    Gene Symbol and Synonyms4931426M20,4933417L02Rik,ANKRD42,Ikbn,PPP1R79,RGD1310789,SARP
    Uniprot AccessionQ8N9B4
    Uniprot Entry NameANR42_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000137494
    Target ClassificationN/A

    The target: ANKRD42, gene name: ANKRD42, also named as PPP1R79, SARP. Predicted to enable NF-kappaB binding activity. Predicted to act upstream of or within positive regulation of NF-kappaB transcription factor activity and positive regulation of cytokine production involved in inflammatory response. Predicted to be located in nucleus. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.